ICCC
NASDAQ
US
ImmuCell Corporation - Common Stock
$6.44
▲ +$0.09
(+1.42%)
Vol 7K
12
Quality Score
ok
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$55.6M
P/E
23.9
ROE
8.0%
Margin
8.4%
D/E
31.85
Beta
0.31
52W
$4–$8
Wall Street Consensus
7 analysts · Dec 20212
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 0.0%
Next Report
May 12, 2026
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | — | — | — |
| Dec 2025 | — | $-0.31 | — |
| Sep 2025 | — | $-0.02 | — |
| Jun 2025 | — | $0.06 | — |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | $6.0M | $7.8M | $8.1M | $6.4M | $5.5M | — |
| Net Income | -$702K | $515K | $1.4M | $502K | -$140K | — |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 6.2% | -1.0% | 6.2% | 6.2% | 6.2% | 8.0% |
| P/E (TTM) | 35.70 | — | 35.43 | 32.04 | 24.34 | 23.94 |
| Net Margin | 7.8% | -1.0% | 6.2% | 6.2% | 6.2% | 8.4% |
| Gross Margin | 43.7% | 33.0% | 37.4% | 37.4% | 37.4% | 40.9% |
| D/E Ratio | 32.81 | 35.07 | 32.81 | 32.81 | 32.81 | 31.85 |
| Current Ratio | 3.85 | 4.12 | 3.85 | 3.85 | 3.85 | 4.21 |
Key Ratios
ROA (TTM)
5.1%
P/S (TTM)
2.00
P/B
1.7
EPS (TTM)
$0.26
CF/Share
$-0.47
Rev Growth 3Y
+11.3%
52W High
$7.60
52W Low
$4.28
$4.28
52-Week Range
$7.60
Financial Health
Free Cash Flow
-$1.8M
Net Debt
$9.7M
Cash
$3.9M
Total Debt
$13.6M
As of Sep 30, 2025
How does ICCC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ICCC valuation vs Biotechnology peers
P/E ratio
23.9
▲
27%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.0
▼
84%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.7
▼
32%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ICCC profitability vs Biotechnology peers
ROE
8.0%
▲
112%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
8.4%
▲
103%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
40.9%
▼
48%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
5.1%
▲
111%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ICCC financial health vs Biotechnology peers
D/E ratio
31.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.2
▼
5%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.3
▼
68%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ICCC fundamentals radar
ICCC
Peer median
Industry
ICCC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ICCC vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BRIGHAM MICHAEL F
Director · Mar 20
25000 shs
Last 90 days
Top Holders
Top 5: 9.02%Vanguard Group Inc
3.35%
$2.0M
Renaissance Technologies, L…
1.67%
$982K
Cresset Asset Management, L…
1.50%
$882K
Morgan Stanley
1.38%
$813K
Bleichroeder LP
1.12%
$662K
As of Dec 31, 2025
Latest News
No related news yet